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Abstract
Background: The Thrombolysis in Myocardial Infarction (TIMI) risk scores for Unstable Angina/Non-ST–elevation myocardial
infarction (UA/NSTEMI) and ST-elevation myocardial infarction (STEMI) and the Global Registry of Acute Coronary Events
(GRACE) risk scores for in-hospital and 6-month mortality are established tools for assessing risk in Acute Coronary
Syndrome (ACS) patients. The objective of our study was to compare the discriminative abilities of the TIMI and GRACE risk
scores in a broad-spectrum, unselected ACS population and to assess the relative contributions of model simplicity and
model composition to any observed differences between the two scoring systems.
Methodology/Principal Findings: ACS patients admitted to the University of Michigan between 1999 and 2005 were
divided into UA/NSTEMI (n=2753) and STEMI (n=698) subpopulations. The predictive abilities of the TIMI and GRACE
scores for in-hospital and 6-month mortality were assessed by calibration and discrimination. There were 137 in-hospital
deaths (4%), and among the survivors, 234 (7.4%) died by 6 months post-discharge. In the UA/NSTEMI population, the
GRACE risk scores demonstrated better discrimination than the TIMI UA/NSTEMI score for in-hospital (C=0.85, 95% CI: 0.81–
0.89, versus 0.54, 95% CI: 0.48–0.60; p,0.01) and 6-month (C=0.79, 95% CI: 0.76–0.83, versus 0.56, 95% CI: 0.52–0.60;
p,0.01) mortality. Among STEMI patients, the GRACE and TIMI STEMI scores demonstrated comparably excellent
discrimination for in-hospital (C=0.84, 95% CI: 0.78–0.90 versus 0.83, 95% CI: 0.78–0.89; p=0.83) and 6-month (C=0.72, 95%
CI: 0.63–0.81, versus 0.71, 95% CI: 0.64–0.79; p=0.79) mortality. An analysis of refitted multivariate models demonstrated a
marked improvement in the discriminative power of the TIMI UA/NSTEMI model with the incorporation of heart failure and
hemodynamic variables. Study limitations included unaccounted for confounders inherent to observational, single
institution studies with moderate sample sizes.
Conclusions/Significance: The GRACE scores provided superior discrimination as compared with the TIMI UA/NSTEMI score
in predicting in-hospital and 6-month mortality in UA/NSTEMI patients, although the GRACE and TIMI STEMI scores
performed equally well in STEMI patients. The observed discriminative deficit of the TIMI UA/NSTEMI score likely results from
the omission of key risk factors rather than from the relative simplicity of the scoring system.
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Introduction
Risk stratification is integral to the management of patients
presenting with Acute Coronary Syndromes (ACS). Current
AHA/ACC guidelines promote the use of the Thrombolysis in
Myocardial Infarction (TIMI) and Global Registry of Acute
Coronary Events (GRACE) risk scores to evaluate the in-hospital
and post-discharge risk of ACS patients [1]. Both of these scoring
systems have been shown to predict the response of ACS patients
to various treatment modalities, and may therefore significantly
influence therapeutic decision-making [2,3,4]. The TIMI risk
scores for Unstable Angina/Non ST-Elevation Myocardial
Infarction (UA/NSTEMI) and for ST-Elevation Myocardial
Infarction (STEMI) patients are simple, integer-based scores
derived from selected clinical-trial cohorts [2,5]. Though slightly
more complex, the GRACE risk scores for in-hospital and 6-
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community-based registry [6,7]. Recent studies have suggested
the superiority of the GRACE risk scores as compared to the
TIMI UA/NSTEMI score in UA and/or NSTEMI patients
[8,9,10]. Comparisons of the TIMI and GRACE scores in STEMI
patients remain unexplored.
This study aimed to evaluate the prognostic abilities of the
TIMI and GRACE risk scores over a broad-spectrum of
community-derived ACS patients (UA/NSTEMI and STEMI)
admitted to a tertiary care center. Moreover, we sought to
investigate the relative contributions of model simplicity and
model composition to any observed prognostic differences between
the TIMI and GRACE risk scores.
Methods
Study population
The study sample consisted of 3451 consecutive patients
admitted to the University of Michigan between January 1999
and December 2005 with a discharge diagnosis of ACS. ACS was
defined as presentation with symptoms of ischemia along with
qualifying electrocardiographic changes, positive cardiac enzymes,
new documentation of coronary artery disease (CAD) or prior
existence of CAD.
The protocol was approved by the institutional review board at
the University of Michigan. Informed consent was obtained for all
patients enrolled after January 1, 2005 following enactment of the
HIPAAPrivacyRule.Patient consentwaseitherwrittenorverbal;as
per the institutional review board, verbal consent was obtained from
subjects who did not return a written consent and/or did not opt out
of the registry. Data were collected bytrained personnel (physicians/
nurses/medical residents) from review of hospital medical records
using a standardized six-page case report form. Demographic
characteristics, medical history, presenting symptoms, duration of
pre-hospital delay, biochemical and electrocardiography findings,
treatment practices and a variety of hospital outcome data were
obtained. Standardized definitions of all patient-related variables
and clinical diagnoses were used. All cases of acute coronary
syndromes were assigned to one of the following categories: ST-
elevation myocardial infarction, non-ST elevation myocardial
infarction, or unstable angina. The outcomes of the study were all-
cause in-hospital and six-month mortality, obtained by six-month
telephone follow-up survey and the Social Security Death Index. In-
hospital mortality data were available for 3451 patients and six-
monthmortalitydata for3170 patients.Foranalysis,theACScohort
was divided into UA/NSTEMI and STEMI subpopulations.
Risk score calculation
All risk scores were calculated from available clinical data on
patient presentation.
TIMI UA/NSTEMI score. The TIMI UA/NSTEMI risk
score (range 0–7) was derived from a cohort of the TIMI 11B
clinical trial for a composite endpoint of mortality, recurrent MI,
and repeat revascularization at 14 days, and consists of seven
equally-weighted, dichotomous variables (Table 1) [2]. In our
database, history of angina was the closest substitute for $2
anginal episodes within the past 24 h; a sensitivity analysis yielded
no change in the overall c-statistic, indicating adequate variable
substitution.
TIMI STEMI score. The TIMI STEMI risk score (range 0–
14) was derived from the Intravenous nPA for Infarcting
Myocardium Early II (IN-TIME II) trial study population to
predict all-cause mortality at 30 days and includes eight variables
of differing weights (Table 2) [5].
GRACE in-hospital and 6-month scores. The GRACE in-
hospital risk score (range 0–372) and the GRACE 6-month risk
score (range 0–263) were derived from the GRACE registry for the
endpoint of all-cause mortality and consist of eight and nine
variables, respectively (Table 3), with published nomograms
outlining the conversion of each variable to its corresponding
point value [6,7].
The TIMI UA/NSTEMI risk score was determined for all UA/
NSTEMI patients and compared against the patients’ correspond-
ing GRACE in-hospital and 6-month risk scores to determine the
overall performance – discrimination and calibration – of each risk
score for predicting in-hospital and 6-month mortality. Similarly,
the TIMI STEMI, GRACE in-hospital and GRACE 6-month risk
scores were assessed in STEMI patients. Comparisons between the
GRACE and TIMI scores were performed using calculated risk
scores and refitted multivariate logistic models. For the latter
approach, original risk score variables were regressed against a
given endpoint (in-hospital or 6-month mortality) with adjusted
beta-coefficients for each variable to optimize model discrimina-
tion within the study population. Established prognostic variables
were then added to the TIMI UA/NSTEMI multivariate model to
evaluate their incremental benefit to model discrimination [11].
Clinical end point
The primary end points of the study were all cause in-hospital
and 6-month mortality.
Statistical analysis
Discrimination indicates the ability of a model to distinguish
between two outcomes and is reported by the c-statistic, equal to
the area under the receiver-operating characteristic (ROC) curve.
Table 1. TIMI UA/NSTEMI risk score.
TIMI UA/NSTEMI RISK SCORE
1) Age $65 1 point
2) $3 risk factors for CAD 1 point
3) Use of ASA (last 7 days) 1 point
4) Known CAD (prior stenosis $50%) 1 point
5) .1 episode rest angina in ,24 h 1 point
6) ST-segment deviation 1 point
7) Elevated cardiac markers 1 point
doi:10.1371/journal.pone.0007947.t001
Table 2. TIMI STEMI risk score.
TIMI STEMI RISK SCORE
1) Age 65–74/.75 2/3 points
2) Systolic Blood Pressure ,100 3 points
3) Heart Rate .100 2 points
4) Killip class II-IV 2 points
5) Anterior STE or LBBB 1 point
6) Diabetes, h/o HTN, or h/o angina 1 point
7) Weight ,67 kg 1 point
8) Time to treatment .4 hours 1 point
doi:10.1371/journal.pone.0007947.t002
ACS Risk Prediction
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capacities of different risk scores for in-hospital and 6-month
mortality [12]. The areas under correlated ROC curves were
compared by a nonparametric approach [13].
The Bayesian Information Criterion (BIC) and the Akaike
Information Criterion (AIC) are variants of the likelihood ratio
that adjust for the number of variables in a model [14]. These
statistics were reported to further assess the incremental contribu-
tion of particular risk factors to the TIMI UA/NSTEMI risk
model.
Calibration assesses the degree of correspondence between
predicted and observed outcomes and can be measured by the
Hosmer-Lemeshow (H-L) statistic for goodness-of-fit. The H-L
statistic was obtained for each risk score and multivariate model
along with its associated p-value; p.0.05 denoted insignificant
difference from the line of perfect agreement and thus good model
fit for the indicated population [15].
Data were analyzed using SAS version 8.2 (Cary, NC). The
authors had full access to all data in the study and take
responsibility for the integrity of the data and the accuracy of
the analysis.
Results
Demographics
Patient demographics for the UA/NSTEMI and STEMI
populations within the total ACS cohort are presented in Table 4.
UA/NSTEMI patients comprised 75% of the ACS cohort. Fifty
percent of all UA/NSTEMI patients were elderly (age $65 years)
compared to 38% of STEMI patients. The age and gender
demographics roughly matched those of the four risk score
derivation cohorts; co-morbidities such as hypertension and
hyperlipidemia were of comparable prevalence to the GRACE
derivation cohorts, but more prevalent than in the TIMI derivation
cohorts (Table S1). For the UA/NSTEMI subpopulation, in-
hospital data were available in 2753 patients and six-month follow-
up data in 2545 patients. For the STEMI cohort, in-hospital data
were available in 698 patients and six-month follow-up data in 625
patients. The in-hospital mortality rate was 4% (n=137) and the
six-month mortality rate was 7.4% (n=234).
Risk score comparisons
Calibration plots of observed versus predicted mortality (Figure
S1 and Figure S2) and H-L statistics (Table 5) for the TIMI and
GRACE risk scores suggested adequate calibration of all four risk
scores for the ACS subpopulations in which they were employed.
UA/NSTEMI. The ROC curves of the appropriate TIMI
and GRACE risk scores for UA/NSTEMI patients are displayed
in Figure 1. For in-hospital mortality (Figure 1A), the TIMI UA/
NSTEMI score yielded a c-statistic of 0.54 (95% CI: 0.48–0.60)
while the c-statistic for the GRACE in-hospital score was 0.85
(95% CI: 0.81–0.89). For 6-month mortality (Figure 1B), the c-
statistics were 0.56 (95% CI: 0.52–0.60) for the TIMI UA/
NSTEMI score and 0.79 (95% CI: 0.76–0.83) for the GRACE 6-
month score. For each time-point, the GRACE risk score
displayed significantly better discrimination than the TIMI score
(p,0.0001, both comparisons).
Comparisons of GRACE and TIMI score distributions between
deceased and surviving UA/NSTEMI patients (Figure 2 and
Figure 3) confirmed the above disparities in discrimination. At
both the in-hospital (Figure 2) and 6-month (Figure 3) timepoints,
there was a clearer differentiation in GRACE score distributions
than in TIMI UA/NSTEMI score distributions between deceased
and surviving patients.
STEMI. In STEMI patients (Figure 4), the TIMI STEMI and
GRACE in-hospital scores yielded c-statistics of 0.83 (95% CI:
0.78–0.89) and 0.84 (95% CI: 0.78–0.90), respectively, for in-
hospital mortality (Figure 3A). At 6-months (Figure 3B), the TIMI
STEMI scoreproduceda c-statisticof0.71(95%CI:0.64–0.79) and
the GRACE 6-month score yielded a c-statistic of 0.72 (95% CI:
0.63–0.81). There was no statistical difference in discrimination
between the appropriate TIMI and GRACE risk scores for in-
hospital and 6-month mortality (p=0.83 and 0.79, respectively).
Consistent with these findings, there was comparable differen-
tiation in the GRACE and TIMI score distribution curves between
deceased and surviving STEMI patients at the in-hospital and 6-
month timepoints (data not shown).
Full logistic models: TIMI UA/NSTEMI analysis
To investigate the observed differences in discrimination
between the TIMI and GRACE risk scores in UA/NSTEMI
patients, full multivariate models of the TIMI UA/NSTEMI and
GRACE in-hospital and 6-month scores were refitted to the UA/
NSTEMI study population; calibration was assessed, and relative
discriminative capacities were then compared for in-hospital and
6-month mortality. For in-hospital mortality, both models were
well-calibrated to the study population (Figure S3A and S3C,
Table 6). The c-statistic of the fitted TIMI UA/NSTEMI model
(0.70, 95% CI: 0.65–0.75; Figure S4A) was significantly greater
than that for the TIMI UA/NSTEMI risk score (C=0.54,
Figure 1A). The c-statistic for the GRACE in-hospital multivariate
model also improved (0.90, 95% CI: 0.87–0.93; Figure S4A), and
was significantly greater than its TIMI UA/NSTEMI counterpart
(p,0.0001). Although the TIMI UA/NSTEMI multivariate
model did not calibrate well (Figure S3B, Table 6), it too displayed
a marked improvement in discrimination (C=0.70, 95% CI:
0.66–0.74; Figure S4B) as compared to the corresponding risk
score (C=0.56, Figure 1B); however, it was significantly inferior to
the GRACE 6-month multivariate model (0.84, 95% CI: 0.81–
0.87; p,0.0001).
Independent predictors of mortality were added to the fitted,
seven-variable TIMI UA/NSTEMI model to assess for improve-
ments in model discrimination. The addition of dichotomous
variables for Killip class (C=0.78), heart rate (C=0.73), and
systolic blood pressure (C=0.74) – each as defined for the TIMI
STEMI risk score – independently enhanced model discrimination
for in-hospital mortality. With all three risk factors, the revised ten-
variable TIMI model was well-calibrated for in-hospital mortality
Table 3. GRACE in-hospital and 6-month risk score variables.
GRACE Risk Score Variables
In-hospital risk score 6-month risk score
1) Age 1) Age
2) Heart Rate 2) H/o Congestive Heart Failure
3) Systolic Blood Pressure 3) H/o Myocardial Infarction
4) Serum Creatinine level 4) Heart Rate
5) Killip class 5) Systolic Blood Pressure
6) Cardiac arrest at admission 6) ST-segment depression
7) Elevated cardiac markers 7) Serum Creatinine
8) ST-segment deviation 8) Elevated cardiac markers
9) No In-hospital PCI
doi:10.1371/journal.pone.0007947.t003
ACS Risk Prediction
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Clinical Characteristics UA/NSTEMI n=2753 STEMI n=698
Age $65 yrs, n (%) 1378 (50.1) 267 (38.3)
Female, n (%) 1013 (36.8) 216 (31.0)
Medical History, n (%)
Myocardial infarction (MI) 1262 (45.8) 166 (23.8)
Congestive heart failure (CHF) 583 (21.2) 67 (9.6)
Hypertension 1989 (72.3) 404 (57.9)
Hyperlipidemia 1813 (65.9) 337 (48.3)
Coronary artery bypass graft 684 (24.9) 58 (8.3)
Peripheral arterial disease 408 (14.8) 62 (8.9)
Atrial fibrillation 302 (11.0) 34 (4.9)
Transient ischemic attack/Stroke 320 (11.6) 54 (7.7)
Current smoker 569 (20.7) 243 (34.8)
Diabetes 896 (32.6) 160 (22.9)
Renal insufficiency 427 (15.5) 50 (7.2)
Presentation
Cardiac arrest, n (%) 40 (1.5) 38 (5.5)
Killip class .II, n (%) 430 (15.6) 112 (16.1)
Blood pressure systolic, mm Hg(mean6SD) 141.8630.0 134.7631.8
Blood pressure diastolic, mm Hg (mean6SD) 77.9620.3 78.9619.2
Heart Rate, beats/min (mean6SD) 79.6621.4 81.2624.4
ST segment depression, n (%) 409 (14.9) 252 (36.1)
Initial Creatinine, mg/dL(mean6SD) 1.361.1 1.260.9
In-Hospital events, n (%)
Congestive heart failure/Pulmonary edema 224 (8.1) 100 (14.3)
Cardiogenic shock 104 (3.8) 73 (10.5)
Cardiac arrest/Ventricular fibrillation 87 (3.2) 71 (10.2)
Sustained ventricular tachycardia 43 (1.6) 15 (2.2)
Atrial fibrillation/flutter 171 (6.2) 63 (9.0)
Myocardial infarction 131 (4.8) 46 (6.6)
Stroke 18 (0.7) 11 (1.6)
Major bleeding/Hemorrhagic stroke 148 (5.4) 57 (8.2)
In hospital therapies, n (%)
Percutaneous coronary intervention (PCI) 1049 (38.1) 494 (70.8)
Aspirin 2661 (96.7) 680 (97.4)
Clopidogrel/Ticlopidine 1071 (38.9) 352 (50.4)
Glycoprotein IIb/IIIa receptor agonists 628 (22.8) 311 (44.6)
Angiotensin receptor blockers/Angiotensin converting enzyme inhibitors 1894 (68.8) 577 (82.7)
Beta blockers (IV or oral) 2491 (90.5) 655 (93.8)
Statins 1982 (72.0) 534 (76.5)
Discharge medications, n (%)
Aspirin 2455 (89.2) 623 (89.3)
Clopidogrel/Ticlopidine 1061 (38.5) 340 (48.7)
Angiotensin receptor blockers/Angiotensin converting enzyme inhibitors 1705 (61.9) 526 (75.4)
Beta blockers 2254 (81.9) 591 (84.7)
Statins 1973 (71.7) 528 (75.6)
In-hospital mortality rate, % (n) 3.41 (94) 6.16 (43)
Six-month mortality rate, % (n) 7.54 (192) 6.72 (42)
doi:10.1371/journal.pone.0007947.t004
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0.78–0.87; Figure 5A). Although heart rate (0.71) and systolic
blood pressure (0.71) added minimally to model discrimination for
6-month mortality, history of congestive heart failure (0.76) –
substituted for Killip class – added noticeable discriminative
power. All three risk factors contributed to a revised ten-variable
TIMI model with adequate calibration (Figure S3F, Table 6) and a
final c-statistic of 0.78 (95% CI: 0.75–0.81; Figure 5B).
Analysis of parsimony and fitting employing the Bayesian
Information Criterion (BIC) and Akaike Information Criterion
(AIC) produced similar results. Addition of the aforementioned
variables to the TIMI multivariate model yielded lower BIC and
AIC values (Table S2), consistent with improvements to the model
and further attesting to the incremental value of these predictors.
Discussion
Our study provides a novel comparison of both GRACE risk
scores and both TIMI risk scores in a broad-spectrum of ACS
patients from a single registry, and uniquely evaluates potential
reasons for the underperformance of the TIMI UA/NSTEMI risk
score in this study population. Specifically, we demonstrate that
the GRACE risk scores are superior to the TIMI UA/NSTEMI
score, but comparable to the TIMI STEMI score in the prediction
of in-hospital and 6-month mortality. Moreover, the full, re-fitted
TIMI UA/NSTEMI multivariate model surpasses the TIMI UA/
NSTEMI risk score in discriminative capacity and improves
greatly with the inclusion of heart rate, systolic blood pressure, and
either Killip class (for in-hospital mortality) or history of CHF (for
6-month mortality).
Risk score comparisons
Prior comparisons of these risk scores in NSTEMI and cardiac
chest pain patients have cited the greater discriminative capacity of
the GRACE scores in-hospital and at 1 year for mortality alone, a
composite endpoint of death and recurrent MI, and the combined
triple endpoint of death, recurrent MI, and recurrent revascular-
ization [8,9,10]. Concordantly, we report significantly higher c-
statistics for the GRACE in-hospital and 6-month risk scores as
compared with the TIMI UA/NSTEMI score for the respective
endpoints of in-hospital and 6-month all-cause mortality.
Our study represents the first direct comparison of the TIMI
STEMI risk score with the two GRACE risk scores for predicting
in-hospital and 6-month mortality within a STEMI subpopulation.
Consistent with previous validation studies [16,17], but in contrast
to its UA/NSTEMI counterpart, the TIMI STEMI score showed
excellent discrimination for in-hospital and 6-month mortality,
Table 5. Hosmer-Lemeshow calibration statistics for the TIMI
and GRACE risk scores.
Risk scores P-values Hosmer-Lemeshow Statistics
TIMI NSTEMI (in-hospital) 0.42 8.14
TIMI NSTEMI (6-month) 0.78 4.83
TIMI STEMI (in-hospital) 0.59 6.55
TIMI STEMI (6-month) 0.83 4.29
GRACE-in hospital (NSTEMI) 0.67 5.77
GRACE-in hospital (STEMI) 0.41 8.23
GRACE-6-month (NSTEMI) 0.68 5.72
GRACE-6-month (STEMI) 0.68 5.70
doi:10.1371/journal.pone.0007947.t005
Figure 1. Comparison of TIMI UA/NSTEMI and GRACE risk scores in UA/NSTEMI patients. Receiver operating characteristic curves of (A)
the TIMI UA/NSTEMI and GRACE in-hospital risk scores for predicting in-hospital mortality, and (B) the TIMI UA/NSTEMI and GRACE 6-month risk
scores for predicting 6-month mortality in patients surviving to hospital discharge.
doi:10.1371/journal.pone.0007947.g001
ACS Risk Prediction
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time point.
Endpoint considerations
Although the TIMI UA/NSTEMI score was created for a
composite endpoint of mortality, recurrent MI, and repeat
revascularization, the difficulties associated with such combined
endpoints – i.e. regional treatment biases including availability of
catheterization laboratories – have been previously noted [7,18].
Moreover, the TIMI UA/NSTEMI score showed better discrim-
ination for mortality alone (C=0.74) than for the composite
endpoint (C=0.65) within its original validation cohort [2]. Our
observations are comparable to those of prior studies that have
reported modest c-statistics for the TIMI UA/NSTEMI score
despite using a combined endpoint of death and recurrent MI
(C=0.59at 1-month [17], and C=0.585 [8]or0.62 [17] at 1-year).
Also, while the TIMI UA/NSTEMI and STEMI scores were
developed for shorter endpoints – 14 days and 30 days,
respectively – prior studies have assessed the TIMI UA/NSTEMI
score at longer time-points, including at 3-months and at 1-year
[8,9,10]. Since a significant risk of adverse events in ACS persists
after the first 30 days, we proceeded to assess these risk scores for
the 6-month endpoint.
Model simplicity, model composition, and variable selection
A risk score’s ease of use generally compromises its prognostic
accuracy, as does application of a risk score to a population distinct
Figure 2. Risk score distributions of UA/NSTEMI patients for in-
hospital mortality. (A) GRACE in-hospital and (B) TIMI UA/NSTEMI risk
score distributions for surviving versus deceased UA/NSTEMI patients
for in-hospital mortality.
doi:10.1371/journal.pone.0007947.g002
Figure 3. Risk score distributions of UA/NSTEMI patients for 6-
month mortality. (A) GRACE 6-month and (B) TIMI UA/NSTEMI risk
score distributions for surviving versus deceased UA/NSTEMI patients
for 6-month mortality.
doi:10.1371/journal.pone.0007947.g003
ACS Risk Prediction
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therefore more accurate than its corresponding risk score, and
refitting of an externally-derived multivariate model to the study
population further improves model discrimination [21,22].
Accordingly, in our analysis, refitted multivariate models conferred
a consistent discriminative improvement over their corresponding
risk scores, most noticeably in the TIMI UA/NSTEMI model.
Despite its improvement from the corresponding risk score, the
discriminative capacity of the refitted TIMI UA/NSTEMI
multivariate model (C=0.70 in-hospital and at 6-months)
remained well below that of the GRACE in-hospital and 6-month
models (C=0.88 and 0.83, respectively), suggesting the limitations
of the seven TIMI UA/NSTEMI variables within the study
cohort. However, inclusion of key heart failure and hemodynamic
variables markedly improved discrimination in the TIMI UA/
NSTEMI model. Thus, model composition may contribute more
than model simplicity to the observed discriminative deficiency of
the TIMI UA/NSTEMI score in our ACS population.
InarecentstudyofNSTEMIpatients,Khotetal.highlightedfive
variables that provided more than 70% of the prognostic
information for 30-day and 6-month mortality: age, Killip class,
heart rate, systolic blood pressure, and ST depression on
electrocardiogram [11].Ofnote,thesefivevariablesarerepresented
in the TIMI STEMI, GRACE in-hospital and GRACE 6-month
risk scores, all of which displayed excellent discrimination in our
ACS population; the TIMI UA/NSTEMI score, however, contains
just two of these five variables (age and ST deviation).
Hemodynamic variables were likely excluded from the TIMI
UA/NSTEMI score to restrict the use of continuous variables and
maintain risk score simplicity for routine clinical use [23]. The
absence of heart failure parameters may be partly attributed to
inherent differences between clinical trial and community-based
ACS populations. Registry populations are generally sicker than
clinical trial-derived cohorts, which typically exclude patients with
comorbidities such as heart failure and renal impairment [24].
Unfortunately, baseline hemodynamic, heart failure, and renal
Figure 4. Comparison of TIMI STEMI and GRACE risk scores in STEMI patients. Receiver operating characteristic curves of (A) the TIMI
STEMI and GRACE in-hospital risk scores for predicting in-hospital mortality, and (B) the TIMI STEMI and GRACE 6-month risk scores for predicting 6-
month mortality in patients surviving to hospital discharge.
doi:10.1371/journal.pone.0007947.g004
Table 6. Hosmer-Lemeshow calibration statistics for the TIMI UA/NSTEMI and GRACE refitted multivariate models.
Risk scores P-values Hosmer-Lemeshow Statistics
TIMI UA/NSTEMI (in-hospital) 0.27 9.93
TIMI UA/NSTEMI (6-month) 0.02 17.55
GRACE-in hospital 0.75 5.08
GRACE-6-month 0.19 11.24
TIMI UA/NSTEMI + Killip/CHF, HR, SBP (in-hospital) 0.11 12.98
TIMI UA/NSTEMI + Killip/CHF, HR, SBP (6-month) 0.58 6.59
doi:10.1371/journal.pone.0007947.t006
ACS Risk Prediction
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to be able to compare associated presenting conditions across the
four derivation cohorts (Table S1). It is likely, however, that limited
enrollment of advanced heart failure patients in the TIMI 11B trial
precluded the incorporation of related variables into the final,
seven-variable TIMI UA/NSTEMI risk score [2,23,25]. Thus, a
risk score derived from a relatively healthier trial population may
not be applicable to patients seen in routine clinical practice.
Our analysis supports the importance of Killip class/CHF,
systolic blood pressure and heart rate – the three missing risk
factors from the TIMI UA/NSTEMI score – by showing their
pronounced incremental value to the TIMI UA/NSTEMI
multivariate model. Even dichotomous versions of these normally
continuous risk factors greatly improved model discrimination
(C=0.82, in-hospital mortality; C=0.77, 6-month mortality)
while preserving the simplicity of the TIMI UA/NSTEMI score.
In fact, the improvements in AIC and BIC attest to the inherent
benefit of these added predictors independent of the number of
variables in the revised model.
Limitations
The present analyses derive from an observational, single
institution study with a relatively small sample size and was thus
subject to various unaccounted confounders inherent to such
investigations. Furthermore, the endpoint differences noted
previously between the TIMI risk scores and those employed in
the study must be taken into consideration.
Conclusions
In accordance with prior findings, we demonstrate the
discriminative benefit of the GRACE scores over the TIMI UA/
NSTEMI score for predicting mortality in our unselected,
community-derived cohort of UA/NSTEMI patients. Additional-
ly, we report similar prognostic capabilities between the GRACE
scores and the TIMI STEMI score in STEMI patients. Due to
their consistent discriminative accuracy in broad spectrum ACS
populations, the GRACE scores may represent the most reliable
risk stratification tools for ACS patient management.
Our findings also suggest that a risk score’s accuracy need not
be compromised significantly by its ease of use, provided it is
comprised of the appropriate predictors. In fact, the sustained
robustness of the TIMI STEMI score, despite its simplicity, lends
considerable support to the importance of variable selection and
model composition in the development of risk scores. Considering
the observed benefits of heart failure and hemodynamic variables
to the TIMI UA/NSTEMI score, it may be both preferable and
feasible to develop a revised risk stratification tool for UA/
NSTEMI patients combining the discriminative power of the
GRACE scores with the inherent simplicity of the TIMI scores.
Supporting Information
Figure S1 Plots of observed versus predicted mortality in UA/
NSTEMI patients for: the GRACE risk scores at (A) in-hospital
and (B) 6-month time-points; and for the TIMI UA/NSTEMI risk
score at (C) in-hospital and (D) 6-month time-points.
Found at: doi:10.1371/journal.pone.0007947.s001 (0.09 MB
DOC)
Figure S2 Plots of observed versus predicted mortality in
STEMI patients for: the GRACE risk scores at (A) in-hospital
and (B) 6-month time-points; and for the TIMI STEMI risk score
at (C) in-hospital and (D) 6-month time-points.
Found at: doi:10.1371/journal.pone.0007947.s002 (0.08 MB
DOC)
Figure 5. Modifications to the TIMI UA/NSTEMI risk model. Receiver operating characteristic curves of the TIMI UA/NSTEMI risk score, the TIMI
UA/NSTEMI refitted multivariate model, and a modified TIMI UA/NSTEMI model including heart failure and hemodynamic variables for predicting (A)
in-hospital mortality and (B) 6-month mortality in patients surviving to hospital discharge.
doi:10.1371/journal.pone.0007947.g005
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NSTEMI patients for: the TIMI UA/NSTEMI refitted multivar-
iate model at (A) in-hospital and (B) 6-month time-points; the
GRACE refitted multivariate models at (C) in-hospital and (D) 6-
month time-points; and the revised, 10-variable TIMI UA/
NSTEMI refitted multivariate model at (E) in-hospital and (F) 6-
month time-points.
Found at: doi:10.1371/journal.pone.0007947.s003 (0.10 MB
DOC)
Figure S4 Receiver operating characteristic curves of (A) the
TIMI UA/NSTEMI and GRACE in-hospital refitted multivariate
models for predicting in-hospital mortality, and (B) the TIMI UA/
NSTEMI and GRACE 6-month refitted multivariate models for
predicting 6-month mortality in patients surviving to hospital
discharge.
Found at: doi:10.1371/journal.pone.0007947.s004 (2.18 MB TIF)
Table S1 Baseline characteristics of patients in risk score
derivation cohorts.
Found at: doi:10.1371/journal.pone.0007947.s005 (0.05 MB
DOC)
Table S2 AIC/BIC values for improvements to TIMI model.
Found at: doi:10.1371/journal.pone.0007947.s006 (0.04 MB
DOC)
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